<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335620</url>
  </required_header>
  <id_info>
    <org_study_id>RTG_60</org_study_id>
    <secondary_id>2010-022907-23</secondary_id>
    <nct_id>NCT01335620</nct_id>
  </id_info>
  <brief_title>The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age</brief_title>
  <official_title>An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, open label, prospective, one phase pharmacokinetic and observational
      study.

      Twenty HIV-1 infected subjects will be recruited, subjects will switch antiretroviral therapy
      to:

        -  tenofovir/emtricitabine 245/200 mg daily (Truvada™) plus

        -  raltegravir 400 mg twice daily On day 28, all subjects will attend for an intensive 24
           hour pharmacokinetic visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IV, open label, prospective, one phase pharmacokinetic and observational
      study.

      Twenty HIV-1 infected subjects will be recruited. Eligible subjects will currently be
      receiving stable antiretroviral therapy with undetectable plasma HIV RNA and have no evidence
      of previous HIV- resistance mutations on genotypic resistance testing.

      At baseline, subjects will switch antiretroviral therapy to:

        -  tenofovir/emtricitabine 245/200 mg daily (Truvada™) plus

        -  raltegravir 400 mg twice daily On day 28, all subjects will attend for an intensive 24
           hour pharmacokinetic visit.

      Follow up over 6 months, subjects will attend on days 14, 90 and 180 for follow up visits
      that will include standard safety parameters. Assessment of cardiac biomarkers at baseline
      and on days 90 and 180 and assessment of neurocognitive function at screening, baseline and
      on day 180 will also be undertaken.

      Following completion of this study, subjects will recommence their usual antiretroviral
      treatment regimen and attend for a study follow up visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>HIV affected over 60 years old</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Levels in Blood</measure>
    <time_frame>Day 28</time_frame>
    <description>rategravir concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Haematology, Biochemistry and Virology Tests</measure>
    <time_frame>6 months</time_frame>
    <description>full blood count, electrolytes and blood lipids will be measured at all visits to assess for changes through out the study. HIV viral load will also be measured to assess the efficacy of the medication at controlling the virus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Disease Markers</measure>
    <time_frame>6 months</time_frame>
    <description>• To investigate cardiovascular disease markers before and after a switch in antiretroviral therapy to raltegravir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Function; Changes in Global Cognitive Z-score</measure>
    <time_frame>6 months</time_frame>
    <description>Cerebral function via cognitive testing before and after a switch in antiretroviral therapy to raltegravir.
Mean Scores from the eight tasks (NPZ-8) assessed were used to derive a global composite measure of neurocognitive function. The result shows the change before and after switch, an increase in z-score represents an improvement in cognitive function assessed by CogState battery, required approximately 10-15 min for completion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Tenofovir/Emtricitabine and Raltegravir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study
tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg twice daily</description>
    <arm_group_label>Tenofovir/Emtricitabine and Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>245 mg once daily</description>
    <arm_group_label>Tenofovir/Emtricitabine and Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>200mg once daily</description>
    <arm_group_label>Tenofovir/Emtricitabine and Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infected males or females

          2. 60 years of age or greater*

          3. signed informed consent

          4. willing to switch therapy as per study protocol

          5. no previous exposure to raltegravir or HIV-1 integrase inhibitors

          6. plasma HIV RNA &lt; 50 copies/mL at screening and on at least one other occasion over the
             last 3 months

          7. currently receiving a stable antiretroviral regimen with no antiretroviral drug
             switches for at least 3 months

          8. no previous clinically-significant resistance documented on HIV-1 genotypic resistance

          9. subjects in good health upon medical history, physical exam, and laboratory testing

         10. BMI above or equal to 18 and below 32

         11. Male subjects who are heterosexually active must use two forms of barrier
             contraception (e.g., condom with spermicide) during heterosexual intercourse, from
             screening through completion of the study.

         12. Have local screening laboratory results (haematology and chemistry that fall within
             the normal range of the central laboratory's reference ranges unless the results have
             been determined by the Investigator to have no clinical significance * 50% of total
             enrolled cohort will be 65 years of age or over. Subsequent to 10 subjects aged
             between 60 and 64 recruited, only subjects aged 65 or over will be eligible.

        Exclusion Criteria:

          1. current alcohol abuse or drug dependence

          2. positive urine drug of abuse screening

          3. active opportunistic infection or significant co-morbidities

          4. current disallowed concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston, MB BH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Boffito</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea &amp; Westminster Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Vera JH, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B, Back D, Boffito M, Winston A. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials. 2015 Jan-Feb;16(1):39-42. doi: 10.1179/1528433614Z.0000000006. Epub 2015 Jan 14.</citation>
    <PMID>25777188</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>September 10, 2019</results_first_submitted>
  <results_first_submitted_qc>October 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2019</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Pharmatokinetic</keyword>
  <keyword>60 years old</keyword>
  <keyword>Raltegravir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada Plus Raltegravir</title>
          <description>Single arm study
Raltegravir: 400 mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada Plus Raltegravir</title>
          <description>Single arm study
Raltegravir: 400 mg twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Levels in Blood</title>
        <description>rategravir concentration</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Plus Raltegravir</title>
            <description>Single arm study
Raltegravir: 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Levels in Blood</title>
          <description>rategravir concentration</description>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1732" lower_limit="969" upper_limit="3095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Haematology, Biochemistry and Virology Tests</title>
        <description>full blood count, electrolytes and blood lipids will be measured at all visits to assess for changes through out the study. HIV viral load will also be measured to assess the efficacy of the medication at controlling the virus</description>
        <time_frame>6 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Plus Raltegravir</title>
            <description>Single arm study
Raltegravir: 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Haematology, Biochemistry and Virology Tests</title>
          <description>full blood count, electrolytes and blood lipids will be measured at all visits to assess for changes through out the study. HIV viral load will also be measured to assess the efficacy of the medication at controlling the virus</description>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Disease Markers</title>
        <description>• To investigate cardiovascular disease markers before and after a switch in antiretroviral therapy to raltegravir.</description>
        <time_frame>6 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada Plus Raltegravir</title>
            <description>Single arm study
Raltegravir: 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Disease Markers</title>
          <description>• To investigate cardiovascular disease markers before and after a switch in antiretroviral therapy to raltegravir.</description>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Function; Changes in Global Cognitive Z-score</title>
        <description>Cerebral function via cognitive testing before and after a switch in antiretroviral therapy to raltegravir.
Mean Scores from the eight tasks (NPZ-8) assessed were used to derive a global composite measure of neurocognitive function. The result shows the change before and after switch, an increase in z-score represents an improvement in cognitive function assessed by CogState battery, required approximately 10-15 min for completion.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada Plus Raltegravir</title>
            <description>Single arm study
Raltegravir: 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Function; Changes in Global Cognitive Z-score</title>
          <description>Cerebral function via cognitive testing before and after a switch in antiretroviral therapy to raltegravir.
Mean Scores from the eight tasks (NPZ-8) assessed were used to derive a global composite measure of neurocognitive function. The result shows the change before and after switch, an increase in z-score represents an improvement in cognitive function assessed by CogState battery, required approximately 10-15 min for completion.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Compare baseline to 24 weeks</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Truvada Plus Raltegravir</title>
          <description>Single arm study
Raltegravir: 400 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Winston</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+442033121603 ext 21603</phone>
      <email>a.winston@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

